Zymeworks Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zymeworks Inc. (Nasdaq: ZYME) is a clinical-stage biotechnology company that develops and commercializes multifunctional biotherapeutics targeting difficult-to-treat cancers and other diseases. The company engineers Azymetric and Zymabod platforms to create bispecific antibodies and multispecific antibody-based molecules; its product candidates include zanidatamab, a HER2-targeting bispecific antibody in Phase 3 trials for biliary tract cancer partnered with Jazz Pharmaceuticals, as well as ZW171, ZW220, and other preclinical and early-stage assets targeting solid tumors and hematologic malignancies. Zymeworks offers contract research and development services through its subsidiaries, focusing on protein engineering and therapeutic design for oncology and autoimmune indications. Founded in 2010 and headquartered in Vancouver, Canada, the company operates primarily in North America with clinical trials and partnerships extending to Europe and Asia. In the last two years, Zymeworks completed a significant strategic transaction with Iconic Therapeutics in 2024, acquiring full global rights to zanidatamab and related HER2-targeted programs following Jazz Pharmaceuticals' return of rights in late 2023, enabling accelerated independent development. The company raised approximately CAD 92 million through a public offering in 2024 to fund zanidatamab's Phase 3 HERIZON-BTC-01 trial and other pipeline advancement. Zymeworks also advanced ZW171 into a Phase 1 trial in 2025 for advanced or metastatic solid tumors, marking a key expansion of its ROR1-targeted portfolio, while streamlining operations to focus on high-potential clinical assets amid a challenging biotech funding environment.
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Q1 Earnings Call Highlights
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Zymeworks (NASDAQ:ZYME) and ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Contrast
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of “Moderate Buy” from Analysts
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME
Neoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical Contrast
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting